Acquired Resistance to Therapy Network (ARTNet)
@NCIARTNet
Followers
393
Following
501
Media
212
Statuses
638
Official Account of @theNCI Acquired Resistance to Therapy Network (ARTNet). https://t.co/4EHNl98ody
Joined April 2020
The Acquired Resistance to Therapy Network (ARTNet), of @theNCI focuses on mechanisms of acquired resistance to cancer therapies & disease recurrence and integrates those findings through team science. Learn more at https://t.co/aSe5ywa2Ei and
cancer.gov
Acquired Resistance to Therapy Network (ARTNet) focuses on the mechanistic bases of acquired resistance to cancer therapies and disease recurrence. Its goal is to balance basic, pre-clinical, and...
0
1
5
In Focus: Translating Artificial Intelligence Breakthroughs into Cancer Diagnostic Breakthroughs https://t.co/AMziNSJvfZ
1
5
7
đź‘Źđź‘Ź#ARTNetPublication
Read our latest #research on #MetabolicCellDeath including #ferroptosis #cuproptosis #disulfidptosis in #CancerTherapy, published with @SpringerNature in @NatureRevCancer
https://t.co/WqrfTRvgPb
@ACKoongMDPhD @BoyiGan @NCIARTNet @MDAndersonNews @MDA_UTHGrad
0
0
0
Register now for the @sitcancer-@theNCI Computational IO Series: Liquid Biopsy Approaches for Cancer Diagnosis and Monitoring: Computational Science in Immuno-oncology đź”— https://t.co/RSNwnYK2XW
@RiyueSunnyBao
0
2
1
Fc-optimized CD40 agonistic antibody elicits tertiary lymphoid structure formation and systemic antitumor immunity in metastatic cancer https://t.co/eilyZLyBSm
0
23
92
ARTNet investigator Dr. Moran Amit of @MDAndersonNews report in @Nature that cancer cells can damage protective nerve coverings, causing nerve injury and chronic inflammation. These injuries drive immune exhaustion and immunotherapy resistance and targeting this pathway may
0
0
0
At today’s Scientific Exchange Meeting, Co-chair Dr. Alan Hutson @Amherst73 of @RoswellPark shared network updates and welcomed new WG Chairs Drs. Herve Tiriac @HerveTiriac & Mark Long @MarkLong_PhD. Dr. Victoria Seewalt of @cityofhope presented on pregnancy-associated BrCa: TME
0
1
2
New study in @JTOonline reveals that ARID1A mutations drive resistance to osimertinib in EGFR-mutant NSCLC. Dual inhibition of EGFR + WEE1 overcomes resistance and suppresses tumor growth in models. ARID1A may serve as a key biomarker & therapeutic target. @BivonaLabUCSF
0
0
0
Online Now: Cell-free DNA fragmentomics in cancer
cell.com
The analysis of cell-free DNA (cfDNA) fragmentation patterns, known as “fragmentomics,” has opened new opportunities in noninvasive cancer diagnostics. In this Review, Tsui et al. explore the...
0
7
43
#ScienceSaturday ❓ Why do some cancers resist immunotherapy? ➡️ A recent study in Nature found that certain cancers can “trick” the body’s immune system. They do this by changing how cells in the bone marrow develop. These changes cause more immune cells called macrophages to
8
80
325
Online now: Intra-tumoral hypoxia promotes CD8+ T cell dysfunction via chronic activation of integrated stress response transcription factor ATF4
cell.com
Metabolic stress imposed by the tumor microenvironment (TME) promotes T cell dysfunction and limits antitumor immunity. Alicea Pauneto et al. demonstrate the hypoxia within the TME drives chronic...
0
5
19
New #JITC article: Dual targeting OX40 and IL-2 receptor enhances antitumor activity through tumor-infiltrating Treg depletion and CD8+ T-cell proliferation https://t.co/OfUlAKMIxl
1
5
20
New Cancer Drug Could Finally Overcome Resistance to Lung Cancer Treatments Researchers found that blocking HDAC11 may stop lung cancer stem cells and overcome drug resistance in NSCLC. https://t.co/uPhrSumz9v
zmescience.com
Researchers found that blocking HDAC11 may stop lung cancer stem cells and overcome drug resistance in NSCLC.
1
7
11
New #JITC article: Real-world outcomes of patients receiving salvage therapies for immune checkpoint inhibitor-resistant Merkel cell carcinoma: a rationale for future clinical trials https://t.co/AmqVqP30ib
@EvanHallMD @PaulNghiem
2
5
15
New in @CD_AACR! 🙌 Scientists demonstrate that loss of CTD acetylation in T cells abrogates CD8+ T cell-dependent antitumor immunity whereas expression of CTD acetylation-mimicking p53 in T cells enhances this immune response. Discover more: https://t.co/jMP3mot2CH
0
2
5
RSK1 reprograms the ubiquitin pathway to promote immune suppression
cell.com
Immunotherapy with PD-1/PD-L1 checkpoint blockade (ICB) is effective in only a minority of cancer patients, suggesting that additional treatment strategies are needed. Peng et al. reveal a novel...
0
3
5